“This financing is an important validation of Altay, of the potential of DX5057 and of what patient-focused, early-stage investment can make possible,” said Eva Chin, Ph.D., Executive Director of SOLVE FSHD. “When we first invested in Altay, we saw an innovative company pursuing a compelling approach to one of the central drivers of FSHD. We paired our financial commitment with sustained scientific and strategic engagement because promising science needs more than capital to reach patients. We are proud to see Altay attract leading life sciences investors and reach this important inflection point.”







